Review Of Pramipexole | Buy Pramipexole 2mg per ML
Review Of Pramipexole | Pramipexole 2mg per ML for Research Purposes
Pramipexole is a dopamine agonist that research suggests may have applications in laboratory studies related to early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS). Research indicates Pramipexole functions by mimicking dopamine activity in experimental settings. It’s crucial to monitor for observed reactions, including adverse reactions and the need for dosage adjustments, when utilizing pramipexole in research environments to ensure protocol integrity and reliable outcomes.
Pramipexole is available from Loti Labs, a trusted supplier for research liquids. The substance comes in liquid form at 2 mg per ml in vials and is strictly intended for research purposes only, not for consumption.
WHAT IS PRAMIPEXOLE? A DOPAMINE AGONIST
Dopamine agonists are a class of substances that mimic dopamine activity in the brain, playing a crucial role in investigating conditions like Parkinson’s disease and Restless Legs Syndrome. Pramipexole is commonly used to treat Parkinson’s disease, helping to manage symptoms and improve quality of life. This compound is a non-ergot dopamine agonist that research suggests may be effective in addressing various Parkinson’s-related symptoms, such as tremors, rigidity, and bradykinesia (slow movements) in laboratory animal models.
Beyond its dopaminergic activity, research indicates Pramipexole demonstrates some affinity to certain serotonergic and adrenergic receptors.
STRUCTURE OF PRAMIPEXOLE
Molecular Formula: C10H17N3 S
Molecular weight: 211.33 g/mol
CAS number: 104632-26-0
IUPAC name: (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
MECHANISM OF ACTION
Animal studies indicate that pramipexole appears to function as a selective dopamine agonist with minimal agonistic activity at other receptors. It is crucial to inform healthcare providers about all medications a patient is taking, as pramipexole may interact with other drugs, potentially increasing its effects or causing drowsiness.
In research contexts, pramipexole has been investigated for its ability to mimic dopamine action in models of Parkinson’s disease and restless legs syndrome. Laboratory findings suggest it demonstrates specificity and potent activity in the D2 subfamily of dopamine receptors in vitro. Research also indicates an affinity for the dopamine D3 receptor subtype rather than other subtypes. Experimental models suggest pramipexole may influence blood pressure, and researchers should be mindful when designing protocols involving position changes. It is also important to consider quantity adjustments when transitioning between different formulations or as test subject responses vary to achieve optimal research outcomes. When using extended release tablets, it is essential to follow prescribed methods of administration and avoid chewing, crushing, or cutting the tablets to ensure proper medication release and effectiveness.
Research data indicates pramipexole is rapidly absorbed in test subjects, reaching peak plasma concentrations in approximately 2 hours. Its terminal half-life appears to be between 8 – 12 hours, and studies suggest it’s primarily eliminated through renal pathways, with 90% of a pramipexole quantity recovered in urine, almost entirely as unchanged compound.
USES OF PRAMIPEXOLE IN RESEARCH
Pramipexole is a potent dopamine agonist that research suggests may have applications in studying Parkinson’s disease models and restless legs syndrome (RLS) analogs. Laboratory investigations indicate that by mimicking dopamine action, pramipexole might influence symptoms such as stiffness, tremors, muscle spasms, and motor control in experimental Parkinson’s models. For RLS research, studies suggest it may affect leg sensations in animal models, potentially offering insights for quality of life investigations. Additionally, pramipexole is utilized to investigate restless legs syndrome in research settings, highlighting its dual role in exploring symptoms of both Parkinson’s disease and RLS. Pramipexole is specifically approved to treat restless legs syndrome, providing essential information about its potential side effects and the possibility of worsening symptoms for RLS patients.
Moreover, pramipexole is widely used in treating Parkinson’s disease, offering significant benefits in managing the disease’s motor symptoms.
PRAMIPEXOLE EFFECTS IN PARKINSON’S RESEARCH MODELS
Research suggests pramipexole may offer several interesting properties:
Influence on Parkinson’s Disease models. Laboratory studies indicate pramipexole might affect Parkinson’s symptoms by mimicking dopamine action in test subjects. Research suggests this compound could be valuable in understanding symptom management and complications in experimental Parkinson models. Additionally, pramipexole is used to investigate Parkinson’s disease in research settings, providing insights into its potential applications. Pramipexole has shown promise in various Parkinson disease research models.
Potential neuroprotective properties against dopamine neuron degeneration following ischemia or methamphetamine exposure in research settings. Studies also highlight the importance of maintaining the same daily dose when transitioning between different formulations to ensure consistent therapeutic effects.
Research applications in cluster headache models, depression studies, and fibromyalgia investigations. Studies suggest pramipexole might also be useful in restless legs syndrome research by affecting leg sensations in experimental models.
INTERACTION STUDIES AND RELATED COMPOUNDS
Research suggests pramipexole may interact with other central nervous system (CNS) substances in laboratory settings, including benzodiazepines, opioids, antipsychotics, and alcohol. Experimental data indicates combining pramipexole with substances that affect blood pressure might produce interesting results related to orthostatic responses.
Laboratory studies indicate antipsychotic compounds may reduce pramipexole effects in research models, while cimetidine appears to influence pramipexole plasma levels by affecting renal clearance. These interactions highlight the importance of carefully designed research protocols when studying this compound in combination with other substances. Additionally, it is crucial to consult a research supervisor before discontinuing pramipexole to avoid withdrawal phenomena in test subjects.
LABORATORY FINDINGS AND EFFICACY STUDIES
Research investigations have explored pramipexole’s effects in models of Parkinson’s disease and restless legs syndrome. In studies using Parkinson’s disease models, research suggests pramipexole significantly influenced motor function and disease indicators, providing valuable data for quality of life research. Pramipexole affects Parkinson’s disease models by mimicking the action of dopamine, thereby providing interesting data regarding tremors, stiffness, and slowness of movement.
Similarly, investigations using restless legs syndrome models indicate that pramipexole appeared to affect symptoms and sleep patterns, suggesting potential applications for further study in this research area.
Research suggests pramipexole may also show promise in Parkinson’s models that have not responded to other compounds, highlighting its potential versatility in experimental settings. Overall, laboratory findings indicate pramipexole may be a valuable tool for researchers studying symptom management in Parkinson’s disease and restless legs syndrome models.
OBSERVED ADVERSE REACTIONS IN RESEARCH SETTINGS
Research indicates the following reactions may be observed due to peripheral and central dopaminergic stimulation:
Involuntary movement patterns
Sudden sleep induction
Orthostatic responses
Consciousness alterations
Changes in mental status indicators
Perceptual anomalies
Behavioral modifications
Postural adjustments
Laboratory observations suggest pramipexole may affect blood pressure in test subjects, and researchers should account for this when designing protocols involving position changes. It is also important to monitor for observed reactions when using pramipexole in research settings to ensure the safety and integrity of the experimental protocols.
Research indicates abrupt discontinuation in experimental protocols may produce interesting observations, so carefully planned tapering schedules are suggested. Additionally, studies suggest pramipexole might influence mental status indicators, including confusion markers and perception alterations, which researchers may wish to monitor during investigations.
ADMINISTRATION CONSIDERATIONS AND DOSE ADJUSTMENTS
In research protocols, if an administration is missed, it’s advisable to proceed as soon as possible. However, if close to the next scheduled administration, skipping the missed application and resuming the regular schedule is recommended. Doubling quantities to compensate isn’t advised, as this may confound experimental results. Additionally, dosage adjustments may be necessary to manage the effectiveness and safety of the treatment, especially in cases of renal and hepatic impairments.
In cases of accidental over-administration, appropriate emergency protocols should be followed. Observed responses might include nausea, drowsiness, or perceptual anomalies. Prompt intervention is crucial for maintaining research integrity. When transitioning from immediate release to extended release formulations, it is important not to alter the extended release versions and to carefully monitor for observed reactions. Extended release tablets should not be chewed, crushed, or cut to ensure proper medication release and effectiveness.
HALF LIFE AND ELIMINATION CHARACTERISTICS
Research suggests pramipexole has a half-life of approximately 8-12 hours, meaning this duration is required for the concentration in test subjects to decrease by half. Studies indicate the primary elimination pathway is renal, with minimal excretion observed in fecal matter. This efficient elimination process helps maintain consistent compound levels in experimental subjects, ensuring reliable research conditions.
STORAGE AND HANDLING RECOMMENDATIONS
Store pramipexole at room temperature, protected from light and moisture to preserve its stability and research utility. Avoid freezing the suspension, and ensure containers remain tightly sealed when not in use. As with all research compounds, keep materials secured and out of reach of unauthorized individuals to prevent accidental exposure. Proper storage and handling are essential for maintaining compound integrity.
SOURCING PRAMIPEXOLE ONLINE FOR RESTLESS LEGS SYNDROME RESEARCH
Pramipexole is available for research purposes from various suppliers. However, it’s essential to verify the quality and reputation of suppliers before obtaining pramipexole for restless legs syndrome research. Consulting with experienced researchers can help determine appropriate experimental parameters and ensure you’re sourcing from reputable providers. This careful approach is crucial for ensuring research validity and reliability.
RESEARCH PROTOCOL CONSIDERATIONS
Research personnel should monitor experimental subjects receiving pramipexole for any signs of altered mental status, including perception changes, confusion, or unusual behavioral modifications. Regular monitoring of blood pressure is also advisable, as research suggests pramipexole may cause orthostatic responses.
Quantity adjustments may be necessary for protocols involving renal impairment models or when studying interactions with other compounds. Starting with lower concentrations and gradually increasing as needed is a recommended approach. For restless legs syndrome research, administration 2-3 hours before sleep observation periods might be considered, with careful documentation of any reactions.
In Parkinson’s disease model research, administering pramipexole with food may help minimize certain reactions. Monitoring for sleep pattern changes, including sudden sleep onset, can provide valuable research data. Researchers should exercise caution with equipment operation after administration until compound effects are well-characterized. Proper protocol management and monitoring can optimize research outcomes and minimize potential confounding variables. Additionally, quantity adjustments are crucial when transitioning between different formulations or as test subject responses vary, ensuring optimal research outcomes.
MISSED ADMINISTRATION AND EXCESS ADMINISTRATION
If you miss an administration of pramipexole in your research protocol, it’s important to apply it as soon as you remember. However, if it’s almost time for your next scheduled administration, simply skip the missed one and continue with your regular schedule. Avoid applying a double quantity to make up for the missed one, as this can lead to complications in your research results.
In the event of an excess administration, immediate protocol intervention is crucial. Responses to excess administration may include nausea, drowsiness, fainting, or perceptual anomalies. If you suspect an excess administration has occurred, contact the national Poison Help hotline at 1-800-222-1222 right away. Prompt intervention is essential to ensure the safety and integrity of your research.
PREGNANCY AND BREASTFEEDING
Pramipexole may not be suitable for research involving pregnancy or lactation models. If your research involves these models, it’s vital to consider the potential risks and benefits of using pramipexole in your experimental design. The effects of pramipexole on prenatal development are not fully understood, and it is not known whether the compound passes into milk. Therefore, careful consideration of these factors is essential when designing research protocols involving reproductive or lactation models.
RESEARCH SUPERVISION INFORMATION
Research supervisors should be aware of several important considerations when overseeing pramipexole studies:
Central Nervous System Effects: Pramipexole is a dopamine agonist that can cause CNS effects such as dizziness, lightheadedness, or fainting. Research subjects with a history of sleep disorders or those receiving sedating substances may be at increased risk of sudden daytime drowsiness.
Substance Interactions: Pramipexole may interact with other substances in laboratory settings, including other research compounds, herbal extracts, and biochemical agents. Regular monitoring of the experimental progress is necessary to adjust the quantity and prevent unwanted effects.
Blood Pressure: Research subjects with low blood pressure or those receiving substances that lower blood pressure may be at increased risk of orthostatic hypotension. Monitoring blood pressure regularly is advisable in research protocols.
Mental Status and Behavioral Changes: Pramipexole may affect mental status and behavioral changes in test subjects, including alterations in goal-directed behaviors, feeding patterns, or reproductive behaviors. Close monitoring for these changes is recommended in research settings.
Rhabdomyolysis Consideration: Research models with a history of rhabdomyolysis or those receiving substances that increase the risk of rhabdomyolysis should be monitored closely.
Experimental Conditions: Pramipexole may not be suitable for certain research models, such as those with kidney or liver function alterations. Quantity adjustments may be necessary for subjects with renal impairment models.
ADVERSE EFFECTS AND MONITORING
Pramipexole may cause various adverse effects, some of which can be serious. It is essential to monitor research subjects closely for signs of these effects and adjust the dose or discontinue treatment as needed.
Common Adverse Effects:
Nausea and vomiting
Headache
Dizziness or lightheadedness
Fatigue or weakness
Insomnia or vivid dreams
Constipation
Dry mouth
Increased urination
Serious Adverse Effects:
Sudden sleepiness or falling asleep during daily activities
Low blood pressure upon standing
Hallucinations or psychotic-like behaviors
Posture changes, such as bent spine syndrome or Pisa syndrome
Muscle breakdown (rhabdomyolysis)
Worsening of restless legs syndrome
Fibrotic complications, such as peritoneal fibrosis, pleural fibrosis, or pulmonary fibrosis
Monitoring:
Regular monitoring of blood pressure is necessary, especially during dose escalation.
Subjects with a history of sleep disorders or taking sedating medications should be monitored closely for signs of excessive daytime sleepiness.
Subjects with a history of mental health conditions, such as psychosis or bipolar disorder, should be monitored closely for signs of worsening mental status.
Subjects with a history of orthostatic hypotension or low blood pressure should be monitored closely for signs of dizziness or lightheadedness.
HEALTHCARE PROVIDER INFORMATION
Prescribing Information:
Pramipexole is a dopamine agonist indicated for the treatment of Parkinson’s disease and restless legs syndrome.
The extended-release tablet is designed to provide a consistent, sustained release of pramipexole over a 24-hour period.
The immediate-release tablet is typically used for patients who require a rapid increase in pramipexole levels.
Dosage and Administration:
The recommended dosage of pramipexole for Parkinson’s disease is 0.125 mg to 4.5 mg per day, divided into three doses.
The recommended dosage of pramipexole for restless legs syndrome is 0.125 mg to 0.5 mg per day, taken 2 to 3 hours before bedtime.
Dose adjustments may be necessary based on patient response and tolerability.
Contraindications:
Pramipexole is contraindicated in patients with a history of hypersensitivity to pramipexole or any of its ingredients.
Warnings and Precautions:
Pramipexole may cause sudden sleepiness or falling asleep during daily activities, which can increase the risk of accidents or injuries.
Pramipexole may cause low blood pressure upon standing, which can increase the risk of dizziness or lightheadedness.
Pramipexole may cause hallucinations or psychotic-like behaviors, especially in elderly patients.
Pramipexole may cause posture changes, such as bent spine syndrome or Pisa syndrome.
Pramipexole may cause muscle breakdown (rhabdomyolysis), which can be serious and potentially life-threatening.
Interactions:
Pramipexole may interact with other central nervous system depressants, such as antihistamines, sedatives, tranquilizers, or sleeping medicine, prescription pain medicine or narcotics, barbiturates, muscle relaxants, or anesthetics.
Pramipexole may interact with alcohol, which can increase the risk of central nervous system effects.
Missed Dose:
If a patient misses a dose of pramipexole, they should take it as soon as they remember.
However, if it is almost time for the next dose, they should skip the missed dose and take the next dose as scheduled.
Withdrawal Symptoms:
Pramipexole may cause withdrawal symptoms, such as anxiety, discouragement, feeling sad or empty, irritability, lack of appetite, lack of feeling or emotion, loss of interest or pleasure, sweating, tiredness, trouble concentrating, trouble sleeping, uncaring, or unusual tiredness or weakness, when it is suddenly stopped or the dose is reduced.
Pregnancy and Breastfeeding:
Pramipexole may be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Pramipexole may be used during breastfeeding only if the potential benefit justifies the potential risk to the infant.
SOURCING PRAMIPEXOLE ONLINE FOR RESTLESS LEGS SYNDROME RESEARCH
Loti Labs provides competitively priced research compounds with comprehensive quality control documentation. We offer detailed technical support and a customer-focused return policy for pramipexole research purposes.
Visit our website or contact our research support team today to obtain pramipexole for your laboratory studies.
References:
Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36. [PMID:7664822]
Massano J, Bhatia KP: Clinical approach to Parkinson’s disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med. 2012 Jun;2(6):a008870. doi: 10.1101/cshperspect.a008870. [PMID:22675666]
Poewe W, Mahlknecht P: The clinical progression of Parkinson’s disease. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S28-32. doi: 10.1016/S1353-8020(09)70831-4. [PMID:20123553]
Authors unspecified: Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 Nov;17(11):939-953. doi: 10.1016/S1474-4422(18)30295-3. Epub 2018 Oct 1. [PMID:30287051]
Aiken CB: Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry. 2007 Aug;68(8):1230-6. [PMID:17854248]
